High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer.
about
Predicting the Response of Neoadjuvant Therapy for Patients with Esophageal Carcinoma: an In-depth Literature ReviewPredictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma.Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy.Predicting response to neoadjuvant therapy in esophageal cancer.ERCC1 single nucleotide polymorphism C8092A, but not its expression is associated with survival of esophageal squamous cell carcinoma patients from Fujian province, China.Early response evaluation and prediction in neoadjuvant-treated patients with esophageal cancer.A Review of ERCC1 Gene in Bladder Cancer: Implications for Carcinogenesis and Resistance to ChemoradiotherapyPredicting response to treatment in gastroesophageal junction adenocarcinomas: combining clinical, imaging, and molecular biomarkers.Circulating mRNA Profiling in Esophageal Squamous Cell Carcinoma Identifies FAM84B As A Biomarker In Predicting Pathological Response to Neoadjuvant ChemoradiationERCC1 mRNA levels can predict the response to cisplatin-based concurrent chemoradiotherapy of locally advanced cervical squamous cell carcinoma.Predictive and prognostic molecular markers in outcome of esophageal cancer.ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiationPossible prediction of the response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy based on gene expression profiling.Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival.Clinical observation of gene expression-guided chemoradiation therapy for nonsurgical esophageal squamous cell carcinoma patients: a retrospective analysis of 36 cases.Locally advanced esophageal adenocarcinoma: current standards and molecular predictors of outcome.ERCC1: impact in multimodality treatment of upper gastrointestinal cancer.Current concepts and future potential in neoadjuvant chemotherapy for esophageal cancer.Predictive genetic markers in neoadjuvant chemoradiotherapy for locally advanced esophageal cancer: a long way to go. Review of the literature.mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines.Excision Repair Cross-Complementation Group 1 Enzyme as a Molecular Determinant of Responsiveness to Platinum-Based Chemotherapy for non Small-Cell Lung Cancer.Gene expression and effects of orally active derivatives of fluoropyrimidine on gastric and colorectal cancer.Neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: a meta-analysis.TaqMan low-density arrays and analysis by artificial neuronal networks predict response to neoadjuvant chemoradiation in esophageal cancer.Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.Role of excision repair cross-complementation 1 expression as a prognostic marker for response to radiotherapy in early-stage laryngeal cancer.A comparative gene-expression analysis of CD34+ hematopoietic stem and progenitor cells grown in static and stirred culture systems.CUL2 and STK11 as novel response-predictive genes for neoadjuvant radiochemotherapy in esophageal cancer.Excision repair cross-complementing group 1 (ERCC1) overexpression inhibits cell apoptosis and is associated with unfavorable prognosis of esophageal squamous cell carcinoma
P2860
Q26777898-31B4FC9D-540A-4200-BF35-B8D3A3CCB1F9Q33729978-27EE62B8-6D56-4176-B021-69606F752527Q33903723-0936A4A9-0A48-4D23-A454-89C231C7CB72Q34022135-504B0FFF-D050-4A73-95C2-7E3FCF885FEDQ34142322-AE0BD1BF-FFD1-4D6A-8BEA-9779B5A96BE6Q34390923-5421155D-23C8-46B0-8F77-1E67321AD9B7Q35495280-BFD70FDD-4A63-4077-BE83-4EE4A572825EQ35583933-A0F3E941-F86F-47BD-A07A-36A49B452A29Q35616720-6944977A-45CA-4E17-908B-8EC913F5744EQ36507567-CB67C26C-A13C-4292-9484-1246B9816D5EQ36636695-7606486E-6891-41F8-9590-10EF4446EA01Q36755127-BAB2BC72-8E7F-4D7C-A7F9-69EF0D3209D6Q36782503-C55F9040-1B2F-4F26-A875-C721A6DF67EAQ37123491-ED65B50D-4C80-46C4-ADC7-A7C1011B7172Q37138374-4A5B9A89-97EE-49EE-8B01-9B05145390A4Q37179405-C414BF9C-0AD5-4AA6-83B8-9768E12E05C0Q37818224-8C275631-99EF-4D1D-9523-731804A1060DQ38631363-F404A041-8F18-4740-BB60-AE553876F6ADQ38728693-DDDE21CA-9A90-4742-8B6A-D5CB702EF5ADQ39979979-6CBDF0DE-36FF-4EF0-95D9-C7E3C1A49F71Q41900593-96949ABE-74FE-4B28-BE79-2C81910A79D0Q42057665-6E23075A-1168-488A-812E-0A223A47A437Q42951422-1B101340-CE2C-405E-A040-80483366B112Q43217461-2150489C-661A-42BE-9004-70B1BECDF1A3Q46770169-90F358E3-6A08-4CFE-945F-B41DBD989E1FQ47097419-D81CE6BF-BC22-4850-96F9-DDB548393CA3Q51131431-35ABFAE5-057E-4760-8FA7-80082F72297DQ54415412-A6409D6C-42D3-4606-AE0A-22861992C520Q58802064-E22E3317-3363-425B-B370-1238B34FD280
P2860
High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
High specificity of quantitati ...... otherapy in esophageal cancer.
@en
High specificity of quantitati ...... otherapy in esophageal cancer.
@nl
type
label
High specificity of quantitati ...... otherapy in esophageal cancer.
@en
High specificity of quantitati ...... otherapy in esophageal cancer.
@nl
prefLabel
High specificity of quantitati ...... otherapy in esophageal cancer.
@en
High specificity of quantitati ...... otherapy in esophageal cancer.
@nl
P2093
P1476
High specificity of quantitati ...... otherapy in esophageal cancer.
@en
P2093
Arnulf H Hoelscher
Elfriede Bollschweiler
Futoshi Miyazono
Hans P Dienes
Hartmut Schaefer
Jan Brabender
Paul M Schneider
Peter V Danenberg
Ralf Metzger
Rolf P Mueller
P304
P356
10.1158/1078-0432.CCR-03-0079
P407
P577
2004-06-01T00:00:00Z